0001104659-23-089937.txt : 20230810 0001104659-23-089937.hdr.sgml : 20230810 20230810184906 ACCESSION NUMBER: 0001104659-23-089937 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230808 FILED AS OF DATE: 20230810 DATE AS OF CHANGE: 20230810 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bastone Bronwen CENTRAL INDEX KEY: 0001927636 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40949 FILM NUMBER: 231161064 MAIL ADDRESS: STREET 1: C/O ENFUSION, INC. STREET 2: 125 SOUTH CLARK STREET SUITE 750 CITY: CHICAGO STATE: IL ZIP: 60603 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Enfusion, Inc. CENTRAL INDEX KEY: 0001868912 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-PREPACKAGED SOFTWARE [7372] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 125 SOUTH CLARK STREET, SUITE 750 CITY: CHICAGO STATE: IL ZIP: 60603 BUSINESS PHONE: (312) 253-9800 MAIL ADDRESS: STREET 1: 125 SOUTH CLARK STREET, SUITE 750 CITY: CHICAGO STATE: IL ZIP: 60603 4 1 tm2323475-2_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2023-08-08 0 0001868912 Enfusion, Inc. ENFN 0001927636 Bastone Bronwen C/O ENFUSION, INC. 125 SOUTH CLARK STREET SUITE 750 CHICAGO IL 60603 0 1 0 0 Chief People Officer 0 Class A Common Stock 2023-08-08 4 A 0 153 0 A 156657 D Class A Common Stock 2023-08-09 4 S 0 55 8.32 D 156602 D Consists of fully vested shares issued under the Enfusion, Inc. 2021 Stock Option and Incentive Plan in connection with the previously disclosed pre-IPO termination of the Enfusion Ltd. LLC Change in Control Bonus Plan (the "Shares"). Consists of shares required by the Issuer to be sold by the Reporting Person to cover tax withholding obligations in connection with the issuance of the Shares, and does not represent discretionary trades by the Reporting Person. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.13 to $8.48. Full information regarding the number of shares sold at each separate price will be furnished to the SEC staff upon request. /s/ Matthew Campobasso, as Attorney-in-Fact 2023-08-10